This study suggested that Lira alleviated HFD-induced kidney injury at least partly via directly restoring renal metabolism, thus GLP-1R agonist is a promising therapy for obesity-associated CKD. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.